Eli Lilly has now sued sellers of retatrutide at every step of the chain: four online peptide vendors, a compounding pharmacy and a California med spa in August 2026, then a weight-loss clinic, a professional practice and more vendors on October 8, 2026. If your clinic ever stocked, administered or advertised retatrutide, you are in the category of business Lilly is suing. These are allegations. No court has ruled on the merits of any of them.
The August 12 round covered vendors, a pharmacy and a med spa
On August 12, 2026, Lilly filed six federal suits and announced them in a company press release. The release says Lilly targeted “compounding pharmacies, medical spas, and online sellers that falsely claim their drugs are for ‘research-use only’ when they are actually intended for human use.” In the same release, Lilly states it “has also referred more than 200 individuals and entities to FDA, the U.S. Department of Justice,” state attorneys general, law enforcement and professional licensing boards. The referrals are not public, and a referral is not a finding.
The licensing-board referrals matter most to you. A board complaint attaches to the license of the clinician who ordered the product.
Lilly uses two legal theories, depending on the defendant
We opened the complaints public on CourtListener as of October 9, 2026.
Against the med spa, false advertising. The complaint against Aesthetic Envy Cosmetic Centers LLC brings a single claim under section 43(a)(1)(B) of the Lanham Act, 15 U.S.C. § 1125(a)(1)(B). Lilly alleges the med spa sold it as “Triple G” and advertised it as superior to Lilly’s approved medicines using Lilly’s own trial data. Lilly asks for an injunction, corrective advertising, disgorgement, damages and fees. The complaint also names the practice’s medical director.
Against the pharmacy and the vendors, state unfair competition. The complaints against Striker Pharmacy, LLC and Lone Star Peptide Co. LLC each plead eight state-law counts: the consumer protection or unfair trade practices statutes of Alaska, Colorado, Connecticut, North Carolina, South Carolina, Tennessee and Washington, plus Texas common law. Each rests on the allegation that selling an unapproved new drug violates that state’s drug law. Lilly alleges Striker, a 503A pharmacy in Katy, Texas, compounded retatrutide and sold it “to medical practices, including med spas,” and shipped it directly to consumers. The complaint calls compounders “an upstream supply link for medical spas and clinics.” The October complaint against an individual seller in Dallas uses the same eight counts.
The October 8 filings reach the clinic level
On October 8, 2026, Lilly filed four more suits. The defendants include MedShape Weight Loss Clinic LLC in Arizona and Southlake Mhya PLLC in Texas. As of October 9, 2026, only one of the four complaints is publicly available, and it concerns retatrutide. The other three dockets show the caption and filing date only, so the product at issue in those three is not yet confirmed from the record.
| Defendant | Type | Court | Docket | Filed |
|---|---|---|---|---|
| Aesthetic Envy Cosmetic Centers LLC | Med spa | E.D. Cal. | 2:26-at-01347 | Aug. 12, 2026 |
| Striker Pharmacy, LLC | 503A compounding pharmacy | S.D. Tex. | 4:26-cv-06563 | Aug. 12, 2026 |
| Astra LLC (Astra Peptides) | Peptide vendor | W.D. Tex. | 5:26-cv-05147 | Aug. 12, 2026 |
| Texas Peptides Inc. | Peptide vendor | W.D. Tex. | 5:26-cv-05146 | Aug. 12, 2026 |
| Lone Star Peptide Co. LLC | Peptide vendor | S.D. Tex. | 4:26-cv-06562 | Aug. 12, 2026 |
| Legendary Peptides, LLC | Peptide vendor | E.D. Tex. | 1:26-cv-00347 | Aug. 12, 2026 |
| MedShape Weight Loss Clinic LLC | Weight-loss clinic | D. Ariz. | 2:26-cv-07361 | Oct. 8, 2026 |
| Southlake Mhya PLLC | Professional practice (PLLC) | N.D. Tex. | 4:26-cv-01294 | Oct. 8, 2026 |
| Cenexa Labs LLC | Not stated on docket | S.D. Tex. | 4:26-cv-08806 | Oct. 8, 2026 |
| An individual defendant | Online peptide seller | N.D. Tex. | 3:26-cv-03514 | Oct. 8, 2026 |
Lilly’s press release lists the Aesthetic Envy case in the Northern District of California. The docket shows the Eastern District, and we use the docket.
The research-use label did not keep vendors out of court
Four August defendants sold retatrutide as a research chemical. Lilly calls the label a pretext. The Lone Star complaint quotes the site’s own disclaimers, “strictly for in vitro laboratory research use only” and “not for human or animal administration,” then points to an age gate, a dose calculator built around bacteriostatic water, and the owner’s social media posts addressed to people at home.
FDA had already taken the same view. In its March 31, 2026 warning letter to Gram Peptides, and again in its August 24, 2026 letter to Peptide Partners LLC, FDA acknowledged the “research use only” statements and concluded that “evidence obtained from your website establishes that your products are intended to be drugs for human use.” Both letters rest on intended use under 21 CFR 201.128 and cite sections 301(d) and 505(a) of the FD&C Act. The Peptide Partners letter adds that selling a reconstitution solution alongside the peptide supplies “the means to prepare an injectable drug for human administration.” FDA’s GLP-1 page, current as of October 1, 2026, states that retatrutide “cannot be used in compounding under federal law.” See our guide to research-use-only peptides and why retatrutide has no lawful pathway today.
For a clinic it is simpler. Once you inject the product into a patient, the research disclaimer no longer describes what happened.
The defendants have a real argument on standing
On October 2, 2026, Legendary Peptides moved to dismiss. Its motion argues that Lilly “does not sell retatrutide, and on its own allegations it cannot,” so Lilly cannot show lost sales from a product it has no lawful market for. It calls Lilly’s future-harm theory speculative, and says two courts in Lilly’s earlier cases rejected a Texas common-law claim built on a state drug law violation. That is a serious question, and the court has not decided it.
Standing is Lilly’s problem against a vendor. It does nothing for you. A loss for Lilly would not change FDA’s position, a board’s view, or your carrier’s. Current status by compound is on our retatrutide status page.
What this means for you
If retatrutide was ever on your menu, treat it as a live exposure, even if you stopped months ago.
- Stop. No new orders, no administration, no refills. Quarantine any remaining stock and document where it is.
- Pull every ad. Website pages, paid ads, social posts, emails, price sheets and any “Triple G” or “GLP-3” product name. Screenshot each with the date before removal.
- Preserve records. Do not delete. Keep invoices, supplier communications, patient charts, consent forms and the screenshots. Destroying records makes every other problem worse.
- Identify your supplier. If the product came from a pharmacy or a research vendor, write down the source now. Our supplier diligence checklist covers what to ask going forward.
- Call counsel before anyone calls you. Check your malpractice policy for notice requirements.
- Talk to your patients. Tell each one you have stopped offering the product and why. Offer an evaluation for an FDA-approved option, such as approved tirzepatide or semaglutide products for chronic weight management, where clinically appropriate. Our weight management program uses approved products.
Our providers do not prescribe retatrutide or any peptide without a lawful pathway. If you need a second set of eyes on your menu, book a call.
Frequently asked questions
Is Eli Lilly suing med spas over retatrutide?
Yes. On August 12, 2026, Lilly sued Aesthetic Envy Cosmetic Centers LLC, a California med spa, for false advertising under the Lanham Act. On October 8, 2026, Lilly filed suits naming a weight-loss clinic in Arizona and a professional practice in Texas. All claims are allegations that no court has decided on the merits.
Does a “research use only” label protect a seller of retatrutide?
FDA and Lilly both say no. FDA’s 2026 warning letters to Gram Peptides and Peptide Partners found that website evidence showed products were intended for human use despite the label. Lilly’s complaints cite age gates, dose calculators and social media aimed at consumers. A clinic that administers the product to patients cannot claim research use at all.
What laws does Lilly use in the retatrutide lawsuits?
The med spa complaint is a single Lanham Act false advertising claim. The pharmacy and vendor complaints we reviewed plead unfair competition under the consumer protection laws of seven states plus Texas common law, each based on the sale of an unapproved new drug. Lilly seeks injunctions, disgorgement of profits, damages and attorneys’ fees.
Can a compounding pharmacy legally make retatrutide?
No. As of October 1, 2026, FDA states that retatrutide “cannot be used in compounding under federal law.” It is unapproved, has no USP monograph and is not on any bulk substances list. Lilly’s complaint against Striker Pharmacy alleges the pharmacy compounded it and supplied med spas. Those allegations have not been proven.
What should my clinic do if we used to offer retatrutide?
Stop all use, take down every ad and social post after screenshotting it, and preserve every record, including invoices and charts. Identify your supplier, call counsel and notify your malpractice carrier if your policy requires it. Then talk with each patient about FDA-approved weight management options where clinically appropriate.
This is general information, not legal advice. Rules vary by state and change. Confirm your own facts with counsel.